These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 11327234

  • 1. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC, Heufelder AE, Erben RG.
    J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
    [No Abstract] [Full Text] [Related]

  • 2. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS.
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract] [Full Text] [Related]

  • 3. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J, Tovar I, Martínez P.
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract] [Full Text] [Related]

  • 4. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC, Heufelder AE.
    Dtsch Med Wochenschr; 2001 Feb 09; 126(6):145-50. PubMed ID: 11233883
    [No Abstract] [Full Text] [Related]

  • 5. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP, Schwarz EM.
    J Cell Biochem; 2006 Feb 01; 97(2):226-32. PubMed ID: 16240334
    [Abstract] [Full Text] [Related]

  • 6. [Merger of bone biology and immunology].
    Suda T, Shima N, Higashio K.
    Tanpakushitsu Kakusan Koso; 2002 Oct 01; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract] [Full Text] [Related]

  • 7. [Molecular mechanism of bone metabolism].
    Kotake S, Utagawa N, Suda T, Kamatani N.
    Nihon Naika Gakkai Zasshi; 2000 Oct 10; 89(10):2046-53. PubMed ID: 11215116
    [No Abstract] [Full Text] [Related]

  • 8. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S, Nakamura K, Takahasi N, Suda T.
    Immunol Rev; 2005 Dec 10; 208():30-49. PubMed ID: 16313339
    [Abstract] [Full Text] [Related]

  • 9. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients.
    Harashima SI, Tsukamoto H, Horiuchi T.
    Rheumatology (Oxford); 2004 Mar 10; 43(3):396-7; author reply 397. PubMed ID: 14963213
    [No Abstract] [Full Text] [Related]

  • 10. [Osteoporosis].
    Chaki O.
    Nihon Rinsho; 2006 Apr 10; 64 Suppl 4():370-4. PubMed ID: 16689336
    [No Abstract] [Full Text] [Related]

  • 11. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI.
    Curr Opin Pharmacol; 2004 Aug 10; 4(4):340-6. PubMed ID: 15251126
    [Abstract] [Full Text] [Related]

  • 12. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF, Bijlsma JW.
    Ned Tijdschr Geneeskd; 2005 Jul 23; 149(30):1664-7. PubMed ID: 16104110
    [Abstract] [Full Text] [Related]

  • 13. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
    Cozzani M, Giovannini I, Naccari R, Penolazzi L, Lambertini E, Borgatti M, Piva R, Gambari R, Siciliani G.
    Prog Orthod; 2005 Jul 23; 6(2):238-47. PubMed ID: 16276433
    [No Abstract] [Full Text] [Related]

  • 14. Bone cancer pain and the role of RANKL/OPG.
    Clohisy DR, Mantyh PW.
    J Musculoskelet Neuronal Interact; 2004 Sep 23; 4(3):293-300. PubMed ID: 15615497
    [Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin deficiency and juvenile Paget's disease.
    Hofbauer LC, Schoppet M.
    N Engl J Med; 2002 Nov 14; 347(20):1622-3; author reply 1622-3. PubMed ID: 12432053
    [No Abstract] [Full Text] [Related]

  • 16. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
    Dovio A, Data V, Angeli A.
    Ann Ital Med Int; 2004 Nov 14; 19(1):8-19. PubMed ID: 15176704
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
    Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P.
    J Rheumatol; 2004 Aug 14; 31(8):1483-90. PubMed ID: 15290725
    [Abstract] [Full Text] [Related]

  • 18. [Recent advance in basic research for osteoporosis].
    Suda T, Miyaura C.
    Nihon Rinsho; 2004 Feb 14; 62 Suppl 2():13-20. PubMed ID: 15035090
    [No Abstract] [Full Text] [Related]

  • 19. Comment on review on T cells in bone biology.
    Smith MD.
    Rheumatology (Oxford); 2004 Oct 14; 43(10):1314; author reply 1314-5. PubMed ID: 15448222
    [No Abstract] [Full Text] [Related]

  • 20. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A, Hasegawa K, Suguro T, Koshihara Y.
    J Rheumatol; 2004 Mar 14; 31(3):426-35. PubMed ID: 14994384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.